RZLT

The constructive part of the March 2026 FDA interaction is that the agency did not shut down sunRIZE after the miss and instead asked for a fuller data package, while the company still has a second Phase 3 program, upLIFT, due in H2 2026. If either the congenital HI review or tumor HI readout restores confidence in ersodetug's efficacy path, the stock has room toward the roughly $4.75 sell-side median target.